Hormone replacement therapy and prognosis in ovarian cancer patients

European Journal of Cancer Prevention

Volumn 22, Issue 1, 2013, Pages 52-58

  Hein, Alexander ^a   Thiel, Falk C ^a   Bayer, Christian M ^a   Fasching, Peter A ^a,b   Häberle, Lothar ^a   Lux, Michael P ^a   Renner, Stefan P ^a   Jud, Sebastian M ^a   Schrauder, Michael G ^a   Müller, Andreas ^a   Wachter, David ^a   Strehl, Johanna ^a   Hartmann, Arndt ^a   Beckmann, Matthias W ^a   Rauh, Claudia ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

estrogen; hormone replacement therapy; ovarian cancer; pathogenesis; prognosis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; PROGESTERONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84871030104     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328355ec22     Document Type: Article

References (35)

1. Albring C, Baum E, Beckermann MJ, Beckmann MW, Blettner M, Bohm B, et al. (2010). Hormone therapy in the peri and postmenopausal women - short version of the S3-guideline. Geburtsh Frauenheilk 70:R64-R76
2. Beckmann MW, Gitsch G, Emons G, Berg D, Ortmann O, Jonat W, et al. (2006). The newly established subspecialty gynecological oncology - a national and an international chance? Geburtsh Frauenheilk 66:123-127
3. Biglia N, Mariani L, Marenco D, Robba C, Peano E, Kubatzki F, et al. (2006). Hormonal replacement therapy after gynaecological cancer. Gynakol Geburtshilfliche Rundsch 46:191-196
4. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. (2010). Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42:880-884
5. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, et al. (2002). CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Res 8:2233-2239
6. Del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, et al. (2003). Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 91:596-602
7. Fasching PA, Ekici AB, Adamietz B,Wachter DL, Hein A, Bayer CM, et al. (2011). Breast cancer risk - genes, environment, and clinical practice. Geburtsh Frauenheilk 71:1056-1066
8. Fathalla MF (1971). Incessant ovulation - a factor in ovarian neoplasiäLancet 2:163
9. Folkerd EJ, Dowsett M (2010). Influence of sex hormones on cancer progression. J Clin Oncol 28:4038-4044
10. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. (2010). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42:874-879
11. Gourlev C, Smyth JF, Mackean M, Stevenson A,Williams A, Rye T, et al. (2006). Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC). J Clin Oncol 24:261S-261SS.
12. Grambsch PM, Therneau TM (1994). Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (3): 515-526
13. Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, et al. (2011a). Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 17:511-518
14. Halon A, Nowak-Markwitz E, Maciejczyk A, Pudelko M, Gansukh T, Gyorffy B, et al. (2011b). Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res 31:711-718
15. Kavanagh JJ, Hu W, Fu S, Deavers M, Moore C, Coleman RL, et al. (2007). Antitumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. J Clin Oncol 25: 5582S-5582SS.
16. Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A (1992). Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects. Gynecol Oncol 47:317-322
17. Krasner C (2007). Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol 106:76-80
18. Kümmel S, Kolberg HC, Lüftner D, Lux MP, Maass N, Schütz F, et al. (2011). Breast cancer 2011 - new aspects. Geburtsh Frauenheilk 71:939-953
19. La Vecchia C (2006). Estrogen-progestogen replacement therapy and ovarian cancer: An update. Eur J Cancer Prev 15:490-492
20. Marshall SF, Chang E, Clarke CA, Cress R, Deapen D, Horn-Ross PL, et al. (2009). Hormone therapy use before diagnosis and breast cancer survival in the California teachers study. Cancer Res 69:79S-79SS.
21. Miller WR (1996). Aromatase inhibitors - where are we now? Br J Cancer 73:415-417
22. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Hogdall E, et al. (2011). Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer 128:2063-2074
23. Pearce CL, Chung K, Pike MC, Wu AH (2009). Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115:531-539
24. Perez-Gracia JL, Carrasco EM (2002). Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research. Gynecol Oncol 84:201-209
25. Purdie D, Green A, Bain C, Siskind V,Ward B, Hacker N, et al. (1995). Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 62:678-684
26. Rao BR, Slotman BJ (1991). Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12:14-26
27. Richardson GS (1972). Endometrial cancer as an estrogen-progesterone target. N Engl J Med 286:645-647
28. Rosenberg L, Palmer JR, Zauber AG,Warshauer ME, Lewis JL Jr., Strom BL, et al. (1994). A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139:654-661
29. Schuetz F, Diel IJ, Pueschel M, von Holst T, Solomayer EF, Lange S, et al. (2007). Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 196:342 e1-342 e9
30. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A,Wozniak E, et al. (2009). A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996-1000
31. Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, et al. (2010). Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res 70:8927-8936
32. Tchekmedyian NS, Liem AK, Quan ET, Burtzo DM, Ucar K (2006). Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer. J Clin Oncol 24:15038S-15038SS.
33. Weiss NS, Szekely DR, English DR, Schweid AI (1979). Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 242:261-264
34. Whittemore AS, Harris R, Itnyre J (1992). Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136:1184-1203
35. Williams CJ (2010). Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 3